These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33141299)

  • 1. The prevalence and locations of bone metastases using whole-body MRI in treatment-naïve intermediate- and high-risk prostate cancer.
    Ottosson F; Baco E; Lauritzen PM; Rud E
    Eur Radiol; 2021 May; 31(5):2747-2753. PubMed ID: 33141299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validating the screening criteria for bone metastases in treatment-naïve unfavorable intermediate and high-risk prostate cancer - the prevalence and location of bone- and lymph node metastases.
    Rud E; Noor D; Galtung KF; Ottosson F; Jacewicz M; Baco E; Lauritzen PM
    Eur Radiol; 2022 Dec; 32(12):8266-8275. PubMed ID: 35939081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
    KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
    BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis.
    Vargas HA; Schor-Bardach R; Long N; Kirzner AN; Cunningham JD; Goldman DA; Moskowitz CS; Sosa RE; Sala E; Panicek DM; Hricak H
    Abdom Radiol (NY); 2017 Jan; 42(1):271-277. PubMed ID: 27480976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
    Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
    J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer in patients from rural and suburban areas--PSA value, Gleason score and presence of metastases in bone scan.
    Szot W; Kostkiewicz M; Zając J; Owoc A; Bojar I
    Ann Agric Environ Med; 2014; 21(4):888-92. PubMed ID: 25528940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    Thomsen FB; Westerberg M; Garmo H; Robinson D; Holmberg L; Ulmert HD; Stattin P
    PLoS One; 2020; 15(1):e0228447. PubMed ID: 31995611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis.
    Tanaka N; Fujimoto K; Shinkai T; Nakai Y; Kuwada M; Anai S; Miyake M; Hirayama A; Hasegawa M; Hirao Y
    Jpn J Clin Oncol; 2011 Oct; 41(10):1209-13. PubMed ID: 21862505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole body MRI (WB-MRI) assessment of metastatic spread in prostate cancer: Therapeutic perspectives on targeted management of oligometastatic disease.
    Larbi A; Dallaudière B; Pasoglou V; Padhani A; Michoux N; Vande Berg BC; Tombal B; Lecouvet FE
    Prostate; 2016 Aug; 76(11):1024-33. PubMed ID: 27197649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
    Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
    Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
    Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
    Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of metastatic deposit in recurrent prostate cancer: a whole-body MRI-based assessment of lesion distribution and effect of primary treatment.
    Pasoglou V; Michoux N; Van Damme J; Van Nieuwenhove S; Halut M; Triqueneaux P; Tombal B; Lecouvet FE
    World J Urol; 2019 Dec; 37(12):2585-2595. PubMed ID: 30826887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective multicenter study of bone scintigraphy in consecutive patients with newly diagnosed prostate cancer.
    Zacho HD; Barsi T; Mortensen JC; Mogensen MK; Bertelsen H; Josephsen N; Petersen LJ
    Clin Nucl Med; 2014 Jan; 39(1):26-31. PubMed ID: 24217537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT.
    Borley N; Fabrin K; Sriprasad S; Mondaini N; Thompson P; Muir G; Poulsen J
    Scand J Urol Nephrol; 2003; 37(5):382-6. PubMed ID: 14594685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI.
    Larbi A; Omoumi P; Pasoglou V; Michoux N; Triqueneaux P; Tombal B; Cyteval C; Lecouvet FE
    Diagn Interv Imaging; 2019 May; 100(5):295-302. PubMed ID: 30704946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.